

METFORMIN ER (GLUMETZA & GENERIC GLUMETZA)

Generic	Brand	HICL	GCN	Exception/Other
METFORMIN ER	GLUMETZA		97061, 97067	

GUIDELINES FOR USE

1. Does the patient have a diagnosis of type 2 diabetes mellitus?

If yes, continue to #2.

If no, do not approve.

DENIAL TEXT: See the denial text at the end of the guideline.

2. Has the patient tried and failed therapy with, or does the patient have a contraindication to **ALL** of the following other metformin products (including each separate supplier)?
 - a. Immediate release Metformin
 - b. Glucophage (brand)
 - c. Metformin (generic Glucophage) manufactured by Amneal, Aurobindo, Heritage Pharma, Major, Mylan, Solco, Sun, Zydus
 - d. Riomet (brand solution)
 - e. Extended release Metformin
 - f. Glucophage XR (brand)
 - g. Metformin ER (generic Glucophage XR) manufactured by Actavis, Amneal, Apotex, Major, Sun, Tagi, Teva
 - h. Fortamet (brand)
 - i. Metformin ER Osmotic (generic Fortamet)

If yes, **approve for 12 months by GCN with a quantity limit of #60 tablets per 30 days.**

If no, do not approve.

DENIAL TEXT: See the denial text at the end of the guideline.

DENIAL TEXT: Our guideline for **Glumetza and its generic** requires a diagnosis of type 2 diabetes mellitus **AND** a trial showing intolerance to every other metformin product marketed in the United States.

RATIONALE

To prevent inappropriate utilization of Glumetza and its generic due to its exorbitant cost without any shown therapeutic benefit. A usual course of Glumetza costs around \$24,000 per year, while generic Glucophage XR (metformin ER) costs around \$100 per year.

FDA APPROVED INDICATIONS

Glumetza is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

REFERENCES

- Valeant Pharmaceuticals International. Glumetza package insert. Bridgewater, NJ. 2016.

Created: 04/17

Effective: 06/01/17

Client Approval: 04/19/17

P&T Approval: N/A